Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 3/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | VCP | P55072 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | PDE2A | O00408 | 3/20 | 0.32 |
| ▸ | AKT1 | P31749 | 2/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.32 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24392676 | 0.88 | CSNK2A2 (0.34) | OPRK1HRH4PDE2AAKT1 | |
| SCHEMBL24392682 | 0.85 | OPRK1 (0.34) | OPRK1CNR1PDE2AAKT1 | |
| SCHEMBL24392146 | 0.83 | OPRK1 (0.36) | IRAK4VCPOPRK1CNR1AKT1 | |
| SCHEMBL24392148 | 0.77 | DPP4 (0.34) | PDE2ADPP4DPP7 | |
| SCHEMBL24391879 | 0.77 | PDE2A (0.34) | CNR1CNR2PDE2A | |
| SCHEMBL24393217 | 0.73 | PDE2A (0.32) | PDE2A | |
| SCHEMBL24391888 | 0.73 | CHRM4 (0.42) | AKT1 | |
| SCHEMBL24392190 | 0.72 | PDE2A (0.34) | PDE2A | |
| SCHEMBL24393334 | 0.71 | PDE2A (0.32) | PDE2A | |
| SCHEMBL24392137 | 0.69 | PDE2A (0.39) | PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220135598-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF | INTEGRAL BIOSCIENCES PRIVATE LIMITED (IN) | 2022-05-05 | — | — | US | disclosed |
| WO-2022091048-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF | INTEGRAL BIOSCIENCES PRIVATE LIMITED (IN) | 2022-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135598-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF | ENPP1, ENPP3, ENPP2 | SMYD3 2613/4885IRAK4 3547/4885VCP 1347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.